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Severe hypoglycaemia (SH) affects approximately 30% of 
individuals with established type 1 diabetes (T1DM) each 
year1,2 and remains one of the most serious and feared 
complications of insulin therapy. It is defined as ‘an event 
requiring assistance of another person to actively administer 
carbohydrate, glucagon or other resuscitative actions’3 and 
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hypoglycaemia.
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Individualised prevention plans are required, emphasising both the need to attend actively to mild hypoglycaemic symptoms 
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can result in collapse without warning, fits or even sudden 
death. SH is often a limiting factor to attaining optimal dia-
betes outcomes, as blood glucose targets may be relaxed in 
order to avoid hypoglycaemic episodes.4,5 In addition to 
safety concerns (for self and others), people with T1DM 
often fear SH, as it can involve unpleasant symptoms, mood 
changes, embarrassment, loss of personal control and inde-
pendence,6–8 resulting in loss of ability to drive safely and 
fulfil family, work and social responsibilities.
The incidence of SH varies in research studies between 
0.2 and 5 events per person per year depending on individual 
characteristics.1 The distribution of events is markedly 
skewed, with a few individuals experiencing a dispropor-
tionately large number of severe events.5 Established risk 
factors for SH include age, duration of diabetes, tight glycae-
mic control, impaired awareness of hypoglycaemia (IAH) 
and previous severe events. IAH is estimated to affect 20%–
25% of unselected clinic populations.9 It is characterised by 
diminished and delayed warning symptoms of impending 
hypoglycaemia10 and is associated with a sixfold increased 
risk of SH when compared to people without IAH.11 Of those 
with IAH, 60% experience at least one episode of SH every 
year,1,11 with an average event frequency of once every 10 
weeks1 and some people having many more events.
Hypoglycaemia is often referred to in ways that suggest it 
is a dichotomous variable (mild or severe),2,12 but in reality, 
individuals experience hypoglycaemia along a continuum. 
Mild hypoglycaemia, which can be readily self-treated, will 
progress to SH if left untreated. This is particularly true in 
those with long-standing T1DM due to the absence of both 
endogenous insulin secretion (which would be reduced dur-
ing hypoglycaemia) and glucagon secretion (the primary 
glucose-raising hormone). Together with progressive failure 
of counter-regulatory hormone responses, particularly sym-
pathoadrenal activation, which also generates symptoms such 
as sweating and tremor, this leads to marked vulnerability in 
those with a duration of diabetes over 15 years.13 As glucose 
remains low or falls further, cognitive and functional impair-
ment deepen, until SH ensues and the assistance of others 
becomes essential to administer glucose and facilitate recov-
ery. Underlying drivers and potential strategies for prevention 
of SH have been reviewed in more detail elsewhere.14
Quantitative and experimental studies have investigated 
the physiological, pathological and (to a lesser extent) psycho-
logical processes underlying hypoglycaemia, resulting in clin-
ical emphasis on absolute avoidance of biochemically low 
glucose levels with the goal of restoring awareness and pre-
venting severe events. Experimental evidence derives largely 
from ‘clamp’ studies, in which hypoglycaemia is induced arti-
ficially in a gradual or step-wise manner through manipulation 
of exogenous insulin and dextrose administration. However, 
hypoglycaemia, as it is experienced in everyday life, may dif-
fer in terms of onset, symptomatology and progression.2
A biopsychobehavioural model of SH has been devel-
oped,2,15 which proposes that people with a history of SH 
probably have very specific profiles of risk factors.16 Yet, 
there remains only limited understanding of the reasons why 
people who retain some awareness of warning symptoms are 
not always able to prevent SH. Recently, qualitative studies 
have been conducted in this field, but they have focused 
either on the experiences of people with IAH,17,18 or their 
family members,19 or on treatment preferences for mild 
hypoglycaemia among adults with T1DM who have attended 
structured education.20 Given the array of established demo-
graphic, clinical and idiosyncratic behavioural risk factors 
involved, we considered that a qualitative study of adults 
with T1DM who have experienced recurrent SH would offer 
valuable insights, as drivers are highly personal and idiosyn-
cratic. While each may be relevant to a subset of people with 
T1DM, the first step in understanding these psychological 
mechanisms is to describe them at the individual level.
Our aim was to conduct a qualitative study of adults with 
T1DM, exploring individual experiences of SH occurring in 
daily life, to understand barriers to the prevention of SH.
Methods
Study design
Qualitative study involving in-depth interviews.
Setting
Two multidisciplinary specialist diabetes clinics (Newcastle 
and Manchester, the United Kingdom).
Sample and recruitment
Purposive sampling was used to recruit 17 adults with estab-
lished T1DM and a history of recurrent SH. In each partici-
pating centre, a medical professional (S.A.L. or M.K.R.) 
approached potential participants to ascertain interest in the 
study and obtain informed consent. Assurance was given that 
consent or refusal to participate would not affect the quality 
of diabetes care or eligibility for any future clinical studies 
and that all information provided would be confidential to 
the study team. A total of 20 adults with T1DM were 
approached, and all were initially willing to participate, 
though three declined (all from Newcastle) for logistical 
reasons.
Ethics
Ethical approval was provided by the National Research 
Ethics Service.
Interviews
Interviews were arranged at a time and location convenient 
to the participant; 12 of the 17 (71%) were conducted in a 
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private room in the hospital, and 5 (29%) were conducted by 
telephone. Mean interview duration was 52 min (range: 34–
69 min). The interviews were conducted by health psycholo-
gists (J.S. and S.M.B.), with no prior relationship to the 
participants. Participants’ demographic data and most recent 
HbA1c (average blood glucose) were obtained from their 
medical records.
Exploratory semi-structured interview techniques were 
used to investigate participants’ experiences of hypoglycae-
mia through open and non-directive discussions about symp-
tom awareness and experience, severity and progression to 
SH. Each interview was guided by an interview schedule 
(Box 1), informed by the literature and professional experi-
ence, which was used flexibly to allow inclusion of new 
issues raised by participants. Interviews were conducted in 
sets of three or four, and the schedule was amended between 
sets to include new issues arising.
Analysis
All interviews were digitally audio-recorded and tran-
scribed verbatim. We used an adapted grounded theory 
approach to analysis,21,22 to explore discrete and overlap-
ping themes in participants’ accounts of their experiences. 
Transcripts were read individually by health psychologists 
(S.M.B. and H.S.) and discussed at length (S.M.B., H.S. 
and J.S.) in an iterative process to allow identification and 
coding of emergent themes. Memos were used to cross-
check and clarify codings between the three psychologists 
(S.M.B., H.S. and J.S.) to develop a cohesive conceptual 
description. All quantitative data are presented as mean ± 
standard deviation.
Results
The sample included 17 participants, nine (53%) of whom 
were women. Participants were aged 46 ± 11 years and had 
lived with T1DM for 26 ± 14 years. All had previously 
attended multidisciplinary structured T1DM education, 
which included specific advice to treat all hypoglycaemic 
episodes primarily with fast-acting refined carbohydrate. A 
total of 13 participants (76%) were currently using insulin 
pump therapy and reported experiencing fewer hypoglycae-
mic episodes since migration from multiple daily injections 
(MDI) to pump therapy. In the previous year, 15 of the 17 
participants had experienced at least one episode of SH 
(with range between 1 and more than 50 events); one had 
experienced episodes of nocturnal hypoglycaemia that were 
disabling but from which recovery occurred without the 
assistance of others, and one had not had an episode of SH 
since commencing pump therapy (despite many previous 
episodes). Hypoglycaemia awareness was not formally 
recorded at the time of the interview, but a broad spectrum 
was evidenced by previous assessment undertaken as part of 
Box 1. Discussion guide for interviews.
1. Experience of recurrent severe hypoglycaemia:
(a) So, let us start then by talking about your experience 
of hypos. What, for you, is the difference between a 
‘mild’ hypo and a ‘severe’ hypo?
(b) Doctors talk about severe hypos being those that 
mean you are unable to treat yourself and need 
someone else’s help. In the past month, how often 
have you had that type of hypo? (What about in 
past 6 months? Can you remember that 
accurately?)
(c) Are you always aware of going hypo? How often do 
you check your blood glucose (BG) levels?
(d) What happens when you have a severe hypo? Can 
you talk me through a ‘typical’ episode – before, 
during and after? (What is that like? How does it 
make you feel?)
(e) Which symptoms do you experience? (Which are 
most frequent, bothersome, help in identifying or 
treating hypo early?)
(f) How do you remember your recent severe hypos?
(g) Do you live alone/with someone/do you have a pet? 
How does that impact your experience?
2. Drivers of recurrent severe hypos:
(a) How do you feel about ... managing your diabetes? 
… controlling your blood sugar levels?
(b) At what sort of glucose levels do you feel happiest?
•• How do you feel when they are lower/higher 
than that? Do higher or lower levels make you 
feel anxious/unhappy and so on; why is that? 
Was it something that your health professionals 
said (e.g. at diagnosis) or does something else 
influence it? Do you avoid high glucose ‘at all 
costs’?
(c) Why do think your blood sugars go low?
•• (Does the person make a link between what he or 
she does and going hypo? Does the person pur-
posefully keep BG low (bordering on SH) or does 
BG go low as part of erratic management/lifestyle 
etc?)
•• (What controls their hypos? Chance, medics, 
self? Simple and basic factors (e.g. less than ade-
quate knowledge about diet/exercise, lifestyle 
changes))
(d) If they purposefully run BG low, Why?
•• (Fear of high BGs/complications? Lack of fear 
of hypos? Anxieties about weight (not snacking, 
etc.)? Depression (people may prefer being out 
of control than responsible for self)? Risky 
behaviours, chaotic control (emotive issues)?) 
Why is that important to you?
Is there anything else you would like to add?
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routine clinical care in both participating centres (including 
individuals with Gold scores10 between 2 and 6). Participants’ 
mean HbA1c was 61 ± 1 mmol/mol; range 45–76 mmol/mol 
(7.7% ± 0.8%; range 6.3%–9.1%).
Participants gave rich and detailed accounts of their indi-
vidual experiences of hypoglycaemia and of the detrimental 
impact of SH on their safety and physical comfort, well-
being and quality of life. The extent of potential distress is 
well illustrated by the words of one: ‘I could be having forty 
winks but the trouble is … those forty winks could turn into 
a coffin’ (M13).
The participants’ own words in Boxes 2–5 illustrate 
common themes. For reasons of brevity, succinct quota-
tions have been selected, and no attempt has been made to 
give equal representation to the experiences of each partici-
pant, although all accounts have been given equal attention 
in our analyses.
Symptoms
Participants described hypoglycaemia mostly in terms of 
progression or deterioration, in which symptoms occur-
ring early during an episode differed from later symptoms 
in terms of type and/or severity (Box 2). It was notable 
that participants experienced impaired concentration or 
attention as an early symptom, with or without additional 
symptoms such as weakness, anxiety, shaking, visual dis-
turbance, palpitations or difficulty breathing. Symptoms 
reported as manifesting early in an episode spanned all 
recognised categories: autonomic (e.g. palpitations, 
sweating, trembling), neuroglycopenic (e.g. weakness, 
confusion) and general malaise (e.g. headache, nausea). 
Later in the progression of an episode, autonomic and 
neuroglycopenic symptoms were also widely reported, 
but general malaise was not.




‘I might start to feel my brain’s not quite 
working properly … It’s the mental side of 
things when I’m slowing down and I notice 
that things aren’t quite right’. (F5)
‘I find it difficult to breathe because my 
diaphragm just didn’t seem to work very 
well and I can’t fill my lungs with air’. 
(M4)
‘I get coloured blotches in front of my eyes’. 
(M3)
‘I get confused and things don’t make sense. I 
get hot, dizzy sweaty and I sometimes get the 
shakes … My vision gets slightly blurred’. 
(F2)
‘The tiredness hits … crying … basically, not 
quite there’. (F1)
‘It’s just like a feeling of weakness … I tend 
to be a bit silly’. (F6)
‘I would just feel kind of slightly shaky’.  
(F7)
‘Sweaty palms and I’ll feel a bit shaky … I 
get a bit snappy’. (M8)
‘Feeling of anxiety … light palpitation … 
concentration wanders …’. (M9)
‘Lack concentration, grate my teeth’.  
(F10)
‘My gums were ideal, because as soon as 
they started tingling I knew straightaway’. 
(F12)
‘With me it’s usually hunger’. (M11)
‘My brain would turn to jelly’. (M13)
Late 
symptoms
‘My arms and legs jerk … my eyes start to 
flicker from side to side’. (F5)
‘It just clouds over and I don’t know what’s 
going on’. (M4)
‘I was twitching and sweating’. (M3)
‘I get the most horrendous hot sweats, which 
turn into cold shivers and proper muscle 
convulsions’. (F2)
‘I … close myself down’. (F1)
‘It was bright and sunny and everything was 
wonderful, and it was just a lovely feeling’. 
(F1)
‘Sweaty … disorientated … panicky’.  
(F6)
‘Very shaky … or a cold sweat … my whole 
body aches’. (F7)
‘Trouble concentrating and a bit agitated’. 
(M8)
‘He [husband] ended up with eight stitches in 
his hand because I bit right through his hand’. 
(F12)
‘It’s like being on an LSD trip’. (M13)
‘I crawled up the street before’. (M14)
‘You struggle and fight people’. (M13)
The code in parentheses refers to participant gender and ID number.
Barriers to prevention
Participant narratives revealed a number of recurring barri-
ers to prevention of SH, relating to cognitive impairment, 
behavioural barriers and psychological factors.
Cognitive impairment (due to neuroglycopenia) was 
described (Box 3) as participants experiencing a ‘window of 
opportunity’ in time during which they could intervene to 
raise blood glucose concentrations and thus prevent progres-
sion to SH. Confusion was evident, with participants describ-
ing not knowing where their own kitchen was or getting to the 
cupboard only to forget why they were there. Some, however, 
also reported that they delayed acting to raise blood glucose 
levels (for as long as an hour), on the basis that they ‘still had 
time’ or that the hypoglycaemia was ‘only mild’.
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Box 4. Behavioural barriers.
Overtreatment 
with insulin
‘I probably overestimate rather than 
underestimate [the amount of insulin 
needed to cover treats/celebration meals] 
… Possibly I might … be taking too much 
insulin … It’s always at the back of my 
mind’. (F10)
Not acting on 
symptoms/
acting too late
‘Sometimes I’ll get warnings and I don’t 
always react to them … There’s some 
times you don’t treat a hypo … you sort 
of block it out, “in a minute, in a minute 
…”’. (F6)
Behavioural barriers (Box 4) emerged as a strong theme 
with a number of action-related sub-themes. These included 
not acting to correct low glucose concentrations (even 
though low blood glucose levels had been identified because 
of symptoms or monitoring results), acting too late, not hav-
ing an appropriate ‘action plan’ to guide self-treatment, not 
having treatment to hand and using inappropriate treatments. 
It was evident that treatment delays could be incurred when 
symptoms were acknowledged but there was something 
more pressing to attend to (e.g. finishing some household 
task or work activity), or when the individual was ‘caught up 
in the moment’ and thinking about something else or relax-
ing (e.g. watching TV) rather than being ‘tuned in’ to the 
symptoms. Participants reported that they did not routinely 
keep a fast-acting glucose source with them at all times (e.g. 
by the bed at night or while working), which meant that 
treatment of mild symptoms was delayed and progression to 
SH made more likely. They also mentioned using treatments 
such as chocolate bars or biscuits, which (because of their fat 
content) are not recommended as a first-line treatment to 
increase blood glucose concentrations rapidly.
‘I just ignore it somehow. In a minute, in a 
minute I’ll act on it’. (F6)
‘I would feel like I could finish doing what I 
was doing and then deal with it’. (F7)
‘Half past 5, 6 o’clock and you’re getting tea 
ready and I’ll remember to do a blood sugar 
before I start or when I’m doing something 
and it’ll be low and I think I’ll just do this 
while I’m getting the “Lucozade” [glucose 
drink] from the cupboard, and you forget. 
It’s more that rather than purposely running 
them low’. (F2)
‘I can do blood glucose while I’m on the 
phone and by the time I’ve finished the 
conversation, I think, “well that was terrible 
because I’m passing out now.” You’ve just 
missed that moment and I do think there’s 
a very fine barrier between “I can now do 









‘I’d sort of sit there with the doors 
open of the cupboard and looking for 
something, you know, and all the time 
time’s ticking away and I’m looking to 
see, well where’s the food?’. (F6)
‘I have to get out of bed and go to find some 
juice’. (M14)
‘It’s a wonderful feeling actually when 
you do make it to the kitchen and do get 
something to eat. “Beat that one. I’ve won 
that one”’. (F1)
‘I can just about stand up, walk downstairs 





‘Your brain’s gone. You’ve got the obvious 
things, the “penguin,” the “kitkat,” a 
biscuit’. (M13)
The code in parentheses refers to participant gender and ID number.
Box 3. Cognitive impairment as a barrier to prevention.
‘I can’t find my way from A to B, so when people say “go 
into the kitchen and get something to eat,” that’s fine but I 
don’t know where my kitchen is’. (F1)
‘I stand in front of the cupboard and think “why am I here?”’. 
(F7)
‘I had a kitkat in my pocket but I took half an hour trying to 
open it before I could get it in my mouth to eat’. (M14)
‘The lower it goes, you get confused’. (M3)
‘It’s just a fuzzy head type of thing. Lack of interest in any-
thing but just total lack of concentration’. (F10)
‘I go sort of … in his words … “a bit glakey”’. (F1)
‘You say, “I’m fine, I’m fine, there’s nothing wrong”’. (F12)
‘You just can’t get your words out’. (F12)
The code in parentheses refers to participant gender and ID number.
Psychological barriers (Box 5) were multifactorial. The 
first set of barriers can arguably be described as an absence 
of protective fear of hypoglycaemia. An absolute focus on 
hyperglycaemia avoidance was a major underlying issue for 
some, who described complete aversion to ‘high’ blood glu-
cose (generally reported as above 10 mmol/L) and somewhat 
phobic behaviour (including overzealous ‘fiddling’ with 
insulin doses) as a result. There was strong overlap, though 
sufficient distinctions were made, between psychological 
burnout, lack of perceived control and preferring the state of 
hypoglycaemia. Those who mentioned these issues had 
experienced many episodes of SH and no longer felt able or 
inclined to deal with them successfully. For one individual, 
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hypoglycaemia was almost a ‘happy place’, one in which 
diabetes became someone else’s problem. This individual 
described liking ‘that better place’ – a detached state of mind 
experienced during hypoglycaemia in which reality faded 
and life’s difficulties could be forgotten. Social embarrass-
ment was a concern, with participants indicating they would 
rather wait to treat a hypoglycaemic episode than leave a 
business meeting early.
Liking ‘that better 
place’
‘I so like that hypo place. I like the fact 
that I can close myself down. I … just 
let the hypo take over. That’s better for 
me than coping with the fact that I have 
hypos, I suppose … I think when I’m in 
hypos I can deal with the world … It’s 
because, when you’re going into a hypo, 
nothing is real’. (F1)
Dislike of glucose 
treatments (gel, 
tablets or drinks)
‘(The gel) you know, it’s so bad that it 
makes you retch’. (F10)
‘I don’t really like glucose tablets. I find 
them quite difficult to eat’. (F7)
‘I avoid the glucose tablets like the 
plague. I really don’t like them’. (M4)
‘You know the glucose ones, they’re 
horrible. They make me sick. I struggle 
to eat them. I struggle to eat one, never 





‘Having hypos doesn’t concern me at all 
in the scheme of things’. (F7)
‘I don’t have any fear of the hypos at 
all’. (F1)
‘I never feel, I never feel panicked when 
I have them. I always feel, you know, 
you’ll be alright but it’s only when it 
gets to that severe stage where I think, 




‘I prefer to let my blood glucose levels 
be a bit too low than to risk putting on 






‘I will make a manual change even if the 
pump tells me zero (if the wizard tells 
me give yourself no correction) … I’ll 
say, “well, I think you’re wrong there. 
I’m going to give this a little bit” … In 
the past what I would do is manually 
apply some compensation myself. I now 
realise that’s wrong … I was worrying 
so much about this hyperglycaemia that 
I was probably over compensating and 
then I was dragging myself into hypos’. 
(M4)
The code in parentheses refers to participant gender and ID number.
Box 5. Psychological barriers.
Hyperglycaemia 
fear/avoidance
‘I’d rather be in a hypo than blind’. (F1)
‘So, for my blood sugar to go up is the 
most frightening thing ever because that 
means I’m going to lose my sight … 
blindness, I really couldn’t deal with. 
Please just shoot me now, don’t let me 
go through that’. (F1)
‘I tend to worry more about hypers than 
hypos’. (M4)
‘You don’t want high blood sugars, 
going to clinics where people have 
had poorly maintained diabetes and all 
the complications, you know, it’s like 
psychological really’. (F6)
‘I probably worry more about going 
high than low, to be honest’. (F7)
‘Hypos doesn’t concern me at all in the 
scheme of things because I understand 
that that’s one of the things that I have 
to put up with. To have good blood 
sugar control is to have hypos, so I 
just don’t think it’s realistic to aim 
for good blood sugar control without 
having them, so to me they’re a kind of 
necessary evil. So, it’s the highs that I 
would get more upset and worried and 
concerned about’. (F7)
‘You know, I don’t want gangrene and I 
don’t want something to go wrong with 
my eyes’. (F10)
Not wanting to 
draw attention to 
oneself
‘It could be very tricky because I’d need 
to leave the room’. (F6)
‘You think, oh, I can’t come out of this 
meeting to go and get my blood tests or 






‘I don’t feel that it is in my control’. (M11)
‘It’s like walking a tightrope. As you go 
and keep walking on it, it gets thinner 
and thinner until eventually you’re in the 
middle, so you’re balancing all the time. 
You know, which way to go … You 
either keep it up or you go hypo. It’s a 
no win situation’. (M14)
‘Sometimes I just don’t want to bother 
any more. It’s a pfaff’. (M13)
Participants also reported significant dislike of the taste of 
glucose tablets, gel or drinks. They described situations where 
they had one of these recommended glucose sources availa-
ble but did not use it, waiting instead until they had found a 
preferred alternative. Additionally, when experiencing symp-
toms indicative of rapidly progressing hypoglycaemia, some 
participants did not use a short-acting glucose source but 
relied instead on a longer acting alternative such as chocolate. 
Some appeared to regard the occurrence of hypoglycaemia as 
an opportunity to eat chocolate, which they would otherwise 
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‘forbid’ themselves from eating, while others evidently 
regarded chocolate as indistinguishable from short-acting 
hypoglycaemia treatments. Indeed, participants whose lives 
were significantly impaired by both recurrent SH and IAH 
used chocolate bars as a preferred primary recovery source. It 
was evident from their narratives that this strategy was the 
result of feeling deprived by a ‘diabetic diet’ and was not 
effective in halting the progression of hypoglycaemia before 
collapse or loss of independent function occurred.
Discussion
Summary of main findings
This is the first qualitative study, to our knowledge, that has 
explored the progression to SH, and barriers to prevention of 
SH, from the individual’s perspective, among adults with 
long-standing T1DM and a history of recurrent SH. A num-
ber of observations arose from these accounts. Awareness of 
hypoglycaemia symptoms, frequent self-monitoring of blood 
glucose and detailed knowledge of how best to raise blood 
glucose concentrations were necessary but not sufficient to 
prevent SH. Beyond this, SH can be understood as a com-
plex phenomenon requiring cognitive capacity; identifica-
tion of activities/times associated with higher risk; 
recognition of early symptoms; a tailored glucose self-mon-
itoring plan to minimise risk/maximise early recognition; a 
specific action plan for treatment of low blood glucose lev-
els; the will to intervene (positive psychological adjustment); 
and timely intervention. If early symptoms of hypoglycae-
mia are associated with mild cognitive deficits (e.g. lack of 
concentration or attention), it becomes even more imperative 
to have a clearly formulated action plan/intervention. Such 
an action plan will allow automaticity to compensate for 
impaired concentration. This will capture the value of acting 
to raise blood glucose concentrations early in the ‘window of 
opportunity’ to thereby prevent progression to SH.
Furthermore, the choice of intervention to raise blood glu-
cose concentrations was likely to be more successful if the 
individual identified a treatment that was preferred (or at least 
palatable). For example, dislike of glucose tablets meant 
some individuals were reluctant to use them despite regarding 
them as a recommended treatment, while other participants 
successfully used alternative, more palatable, treatments. The 
choice of intervention also influences progression to SH. 
While fast-acting treatments (e.g. glucose, fruit juice, jelly 
beans) will be suitable either early or late in the progression, 
slow-acting treatments (e.g. chocolate, biscuits) may take too 
long to raise blood glucose concentrations and be particularly 
problematic if used later in an episode. The choice of inter-
vention will influence blood glucose levels post episode. If an 
excessive dose of fast-acting glucose is used (or excessive 
quantities of slow-acting treatments are eaten), this is likely 
to result in rebound hyperglycaemia and a consequent delay 
in achieving glycaemic stability.
The validity of these findings is supported by our clinical 
observations and evidence from other studies. The idiosyn-
cratic nature of hypoglycaemia is well recognised,23 as is the 
occurrence of transient hypoglycaemia-induced cognitive 
impairment or poor concentration as a reliable indicator of 
low blood glucose concentrations.24,25 Historically, much 
emphasis has been placed on autonomic symptoms as key to 
the detection and prevention of hypoglycaemia. However, 
our findings suggest that the earliest warning sign experi-
enced by many people was mild cognitive impairment and 
that progression to SH occurred despite recognition of these 
symptoms. This is consistent with findings elsewhere. 
Gonder-Frederick et al.7,15 emphasised that neuroglycopenic 
symptoms should be regarded as of equal value to autonomic 
symptoms in detection of hypoglycaemia, and cognitive 
impairment is a key driver in the biopsychobehavioural 
model of hypoglycaemia. Likewise, it has been reported pre-
viously that people with insulin-treated diabetes who have 
optimal glycaemic control experience a decline in mental 
performance before the onset of warning symptoms of hypo-
glycaemia.2 As others have noted,20 education is a pre-requi-
site for an appropriate response to impending hypoglycaemia. 
Furthermore, as noted elsewhere,20 dislike for recommended 
treatments, such as glucose gel or dextrose tablets, suggests 
that the range of treatment options needs to be explored fully 
by an understanding clinician to minimise habitual choice of 
less immediately effective primary interventions. Finally, 
recent neuro-imaging studies indicate that IAH is associated 
with a reduced ability to perceive hypoglycaemia as unpleas-
ant or dangerous, which may undermine motivation and abil-
ity to act in appropriate ways to prevent or delay SH.26 
Narrative accounts of delays in taking appropriate actions 
may be explained, at least in part, by these latest findings. A 
psycho-educational programme has now been developed 
which may offer benefit to those with an inappropriate lack 
of concern about hypoglycaemia, for whom traditional edu-
cational approaches have not been sufficient.27
Strengths and limitations
The validity of our findings is further supported by the num-
ber of interviews conducted and by the frequency with which 
similar themes emerged during our careful cross-checking of 
the data. It is a strength of the grounded theory approach to 
analysis used in this study that the themes themselves (in this 
case barriers to the prevention of hypoglycaemia) derive 
directly from the narrative of individual participants and, as 
such, are more likely to represent an accurate reflection of 
hypoglycaemia progression than would interviewer- or ques-
tionnaire-driven accounts. The way in which people are 
asked to describe their individual symptoms of hypoglycae-
mia influences their accounts,2 and rank order of symptoms 
has been shown to vary if people are asked to attribute rele-
vance ratings to their reporting of symptoms.23 By eliciting 
unprompted narratives about the way hypoglycaemic 
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episodes manifest through time, this study offers valuable 
insights into the relative usefulness of specific symptoms as 
cues to prompt self-treatment. Moreover, the processes by 
which symptoms are ignored or not acted upon in everyday 
life can be better understood.
Given the qualitative nature of this study, we are cautious 
not to overgeneralise the findings. The insights reported here 
have implications for the prevention of recurrent SH but may 
be less relevant to those with T1DM who have little history 
of SH and experience only isolated episodes with clearly 
identifiable precursors. Hypoglycaemia awareness status 
was not formally assessed using quantitative measures at the 
time of the interview or by recruiting physicians. Given the 
focus on a qualitative approach by independent interviewers, 
we aimed to minimise potential for bias and encourage open 
and honest interviews by avoiding immediately preceding 
health-care professional assessments/questionnaires, which 
could be perceived as directing ‘acceptable’ responses. 
Nevertheless, participants were selected to encompass a 
broad range of preceding hypoglycaemia awareness despite 
their shared experience of SH.
Several other caveats apply: this study included a largely 
Caucasian sample. It was conducted in only two UK tertiary 
diabetes centres, although the interviewees comprised a sub-
stantial proportion of the people with recurrent SH in each 
centre. Recall of SH is considered highly reliable for up to 12 
months;28 while most participants had experienced at least 
one episode within this time frame, there was unavoidable 
reliance on participant recall, as well as participants’ and 
interviewers’ interpretation of symptoms and factors influ-
encing progression to SH. It follows that we can only con-
sider these findings to be useful insights rather than facts. 
Nonetheless, at least some of the barriers identified may be 
contributory factors whenever SH occurs in the context of 
retained symptom awareness, and recognition of these barri-
ers may contribute to avoidance of SH.
Implications for future research or clinical 
practice
Clinical practice guidelines for the management of adult 
hypoglycaemia state the imperative to address the issue of 
hypoglycaemia ‘in every contact with patients with drug-
treated diabetes, particularly those treated with insulin secre-
tagogue or insulin’ (p. 721).5 Moreover, it is accepted that 
early intervention to stop progression towards a more severe 
event is always preferable.5 Unfortunately, the ‘window of 
opportunity’ to act diminishes over time. The findings of this 
study serve to identify individualistic barriers to hypoglycae-
mia prevention and to suggest ways in which these barriers 
can be overcome through patient-centred clinical care.
The value to the individual of having intact symptomatic 
awareness of hypoglycaemia is well recognised. However, 
transient neuroglycopenic symptoms of mild cognitive 
impairment such as lack of concentration (or ‘fuzzy 
thinking’) are likely to be particularly useful cues to prompt 
a ‘just in time’ dose of glucose since further deterioration in 
cognitive function makes successful self-treatment increas-
ingly less likely. Indeed, it may be possible to identify a spe-
cific ‘complex’ cognitive task that the individual usually 
finds straightforward but becomes difficult during hypogly-
caemia (such as a mental arithmetic calculation or writing 
test), which an individual can adopt, as a check to confirm or 
exclude insipient hypoglycaemia requiring treatment. Such a 
task would have the added benefit of screening for potential 
hyperglycaemia in individuals for whom subtle symptoms 
can be experienced during both hypo- and hyperglycaemia 
but may not be otherwise differentiated. Moreover, the 
development of a clear personalised action plan for early 
intervention is also central to prevention, particularly where 
impaired concentration/attention may cause delay in treat-
ment. Individuals can be encouraged to consider and prepare 
for possible hypoglycaemia so that implementing their own 
personal action plan to raise glucose becomes both automatic 
and immediate in order to prevent progression to SH.
Likewise, it may be of significant value to reinforce the 
importance of using a minimal dose of fast-acting treatment 
(e.g. glucose, fruit juice). This recommendation is part of 
many established diabetes structured education programmes, 
such as Dose Adjustment For Normal Eating (DAFNE),29 
which have demonstrated significant reductions in SH17,30,31 
but may not be reinforced sufficiently in individual consulta-
tions, informed by sensitive exploration of potential barriers 
to following this advice. While all glucose sources will even-
tually achieve the goal of normoglycaemia, use of slow-act-
ing glucose late in the progression of a hypoglycaemic 
episode may not raise blood glucose concentrations in time 
to prevent loss of function or collapse. Moreover, a larger 
than necessary dose of glucose at any stage will complicate 
the return to optimal blood glucose levels, leading to rebound 
hyperglycaemia and the use of additional short-acting insu-
lin, thereby precipitating further hypoglycaemic episodes. 
For some individuals, fear of rebound hyperglycaemia after 
treatment creates reluctance to treat hypoglycaemia at an 
early stage, but clinicians can emphasise the success of an 
appropriate dose in preventing SH without ensuing hyper-
glycaemia. Such fears, resulting in absolute hyperglycaemia 
avoidance, can also be a contributing psychological factor 
and have been recognised elsewhere.32
Finally, adaptation of treatment recommendations to per-
sonal preference is valued by many individuals and will fur-
ther enhance willingness to treat mild hypoglycaemia and 
increase likelihood of SH prevention. For example, accom-
modating a dislike of glucose tablets or drinks, and substitut-
ing these with a suitable alternative, such as jelly beans, can 
eliminate potential reluctance to treat early symptoms.
As these personal accounts illustrate, hypoglycaemic 
symptoms are idiosyncratic and also differ intra-individually 
between episodes. Individual cognitive, behavioural and 
psychological barriers to the prevention of SH exist 
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(independent of treatment risks), and it seems likely that 
these specific factors need to be addressed by the individual 
and his or her medical team if recurrent SH is to be avoided. 
Psycho-educational interventions for people at risk of SH 
may likewise offer the greatest benefit if they reflect a multi-
factorial approach, cognisant of all the potential underlying 
barriers identified in this study. Recent qualitative research 
with people who have IAH suggests that cognitive biases 
may impair individuals’ ability to instigate behaviours that 
facilitate hypoglycaemia avoidance and/or regained aware-
ness of hypoglycaemia.15 However, SH may be experienced 
by many people who have retained hypoglycaemia aware-
ness as well as those with impaired or absent awareness, and 
our data support that the route to hypoglycaemia prevention 
may need to be tailored accordingly. Informed by the insights 
gained from this study, a brief psycho-educational interven-
tion has been developed with the specific goal of preventing 
SH in those with reduced awareness of hypoglycaemia and/
or previous severe events. It has been named the ‘Hypo 
COMPaSS’ educational tool, and as part of its initial valida-
tion, it has been used by all participants in an ongoing inter-
ventional trial (ISRCTN52164803).28
Conclusion
In summary, our qualitative data highlight the multifaceted 
and idiosyncratic nature of SH and provide rich personal 
accounts. They support clinical observations and previous 
quantitative findings that individuals with a history of recur-
rent SH may have specific thought and behaviour risk pro-
files. Individualised prevention plans for these people should 
emphasise both the need to attend actively to individual 
symptoms of mild hypoglycaemia and to intervene promptly 
(at personal cues) with an appropriate and acceptable glucose 
source in order to prevent progression to SH. For some, fur-
ther work to cognitively reframe SH may be needed, particu-
larly among those with extreme hyperglycaemia avoidance.
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